FVIII-CAART

N/A

Report date: 2023/12/07 10:01:53

Base Information

Drug NameFVIII-CAART

Drug Alias NameFVIII-CAART

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCoagulation factor X stimulants

TargetsCoagulation factor X

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesCabaletta Bio Inc

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A